Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Goodwill & Intangibles (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Goodwill & Intangibles for 6 consecutive years, with $13.7 million as the latest value for Q1 2026.

  • For Q1 2026, Goodwill & Intangibles fell 35.4% year-over-year to $13.7 million; the TTM value through Mar 2026 reached $13.7 million, down 35.4%, while the annual FY2025 figure was $14.3 million, 34.9% down from the prior year.
  • Goodwill & Intangibles hit $13.7 million in Q1 2026 for Barinthus Biotherapeutics, down from $14.3 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $43.3 million in Q1 2022 and bottomed at $13.7 million in Q1 2026.
  • Average Goodwill & Intangibles over 5 years is $31.5 million, with a median of $36.5 million recorded in 2024.
  • Year-over-year, Goodwill & Intangibles dropped 7.83% in 2023 and then tumbled 57.34% in 2025.
  • Barinthus Biotherapeutics' Goodwill & Intangibles stood at $40.5 million in 2022, then decreased by 7.83% to $37.3 million in 2023, then plummeted by 41.17% to $21.9 million in 2024, then plummeted by 34.9% to $14.3 million in 2025, then fell by 4.35% to $13.7 million in 2026.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods came in at $13.7 million, $14.3 million, and $14.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.